[PDF] Monitoring of medical literature and the entry of relevant information

View - Download Monitoring of medical literature and the entry of relevant information

Previous PDF

Next PDF

30 Churchill Place ł Canary Wharf ł London E14 5EU ł United Kingdom

An agency of the European Union

Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5525 Send a question via our website www.ema.europa.eu/contact

© European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged.

22 December 2016

EMA/848710/2016

, Rev. 2

Inspections

Human Medicines Pharmacovigilance and Committees Monitoring of medical literature and the entry of relevant

information into the EudraVigilance database by the

European Medicines Agency

Questions and

Answers

Draft prepared by Project and Maintenance Group 1

"Collection of key information on medicines" (PMG 1) of the governance structure for pharmacovigilance

18 May 2015 Consultation of the EudraVigilance Expert Working Group (EV-

EWG) 29 May 2015

Finalised by Project and Maintenance Group 1 (PMG 1) 2 June 2015 Updates based on completion of the launch phase 28 August 2015

Draft revision prepared 12 December 2016

Rev 2* approved by Pharmacovigilance Business Team 1 16 December 2016

This Questions and Answers

(Q&A) document addresses a first set of frequently asked questions from marketing authorisation holders in preparation of the implementation of the monitoring of medical

literature and entry of adverse reaction reports into EudraVigilance by the Agency in line with Article

27 of Regulation (EC) 726/2014.

This Q&A document will be regularly updated based on further questions received. All questions and answers are subject to evaluation and agreement by the pharmacovigilance governance.

Updates will be published at the

dedicated MLM webpage of the Agency. *Revision 2 includes a revised question 001 &, minor grammatical changes to some answers, replacement of question 006 with question 045 and addition of questions 46 - 48

Monitoring of medical literature and the entry of relevant information into the EudraVigilance database by the European Medicines Agency

EMA/848710/2016 Page 2/25

Reference

ID

Question Answer

001 What is day zero for the

marketing authorisation holder?

The day when the article is

available on the EudraVigilance website or when the European

Medicines Agency (EMA) found the

article in the dedicated literature reference databases? The clock start for the reporting of a valid ICSR (day zero) is defined in GVP Module VI, chapter

VI.B.7. Reporting of Individual case safety reports (ICSRs). More specifically it is stated that "For

ICSRs described in the scientific and medical literature (see VI.B.1.1.2.), the clock starts (day zero)

with awareness of a publication containing the minimum information for reporting. Where contractual arrangements are made with a person/organisation to perform literature searches and/or report valid ICSRs, detailed agreements should exist to ensure that the marketing authorisation holder can comply with the reporting obligations". Furthermore, GVP Module VI, chapter VI.App2.7. "Day zero" indicates that "although with weekly

literature searching, day zero for a reportable adverse reaction present in an abstract is taken to be

the date on which the search was conducted. For articles that have been ordered as a result of literature search results, day zero is the date when the minimum information for an ICSR to be valid is available". For ICSRs described in the scientific and medical literature monitored by the Agency in accordance with Article 27 of Regulation (EC) 726/2004, the clock starts (day zero) with awareness of a

publication containing the minimum information for reporting. In practice this means that for records

of confirmed ICSRs, the clock starts for marketing authorisation holders at the time of the publication

of the outcome of the literature screening result "MLM Search Results" on the dedicated area of the EudraVigilance website. For records of potential ICSRs, the day zero is the date when the minimum information for an ICSR to be valid is available. For ICSRs described in the scientific and medical literature monitored by the Agency in accordance with Article 27 of Regulation (EC) 726/2004, the clock starts (day zero) with awareness of a publication containing the minimum informat ion for reporting. In practice this means that for records of confirmed ICSRs, the clock starts for the MLM Service at the time of performing the search; whereas for marketing authorisation holders the clock starts when the information on which substances are suspected to have caused a reaction is made available to marketing authorisation

Monitoring of medical literature and the entry of relevant information into the EudraVigilance database by the European Medicines Agency

EMA/848710/2016 Page 3/25

Reference

ID

Question Answer

holders. This information is first made available when the ICSR is transmitted to EudraVigilance; therefore the date of transmission of an ICSR by the MLM Service to EudraVigilance is day zero for marketing authorisation holders in the EEA. For records of potential ICSRs, the day zero for the MLM service is the date when the minimum information for an ICSR to be valid is available.

For further details please refer to the Detailed guide regarding the monitoring of medical literature

and the entry of relevant information into the EudraVigilance database by the European Medicines

Agency (Doc. Ref. EMA/161530/2014).

00

2 When will the full production start

and which medicinal products are included in the service?

The start of the

full operation of the MLM service will take place on 1 September 2015 and will cover the top 300 active chemical substance groups and 100 herbal groups. The top 300 active chemical substance groups can be identified using the list "Medical literature monitoring: substance and herbal substance groups" as published at the dedicated MLM webpage. 00

3 Will marketing authorisation

holders still need to do literature screening for brand names for the substance groups included in the

Medical Literature Monitoring

(MLM) service? The search strategy for each substance group included in the MLM service provided by the Agency will include brand names based on the following principle (see Detailed guide regarding the monitoring of medical literature and the entry of relevant information into the EudraVigilance database by the European Medicines Agency: Doc. Ref. EMA/161530/2014): "Substance Group is constituted of multiple components. The first component will be the INN name. The other components will be alternative names (variants) for the substances based on the Extended EudraVigilance Medicinal Product Dictionary (xEVMPD) or other reference sources". Alternative names (variants) will include medicinal product names (brand names) based on the information submitted by marketing authorisation holders in accordance with

Article 57(2), second

subparagraph of Regulation (EC) 726/2004 as well as variants for medicinal product names that have been reported in ICSRs to EudraVigilance. The search strategies will be published at the dedicated MLM webpage.

Monitoring of medical literature and the entry of relevant information into the EudraVigilance database by the European Medicines Agency

EMA/848710/2016 Page 4/25

Reference

ID

Question Answer

00

4 If an individual case resulting

from the MLM service of the

Agency and created in

EudraVigilance already exists in

the marketing authorisation holder"s safety database - does the marketing authorisation holder need to provide the EMA case number as follow-up information? In GVP Module VI, chapter VI.C.6.2.2.7. "Follow-up information" it is stated that "marketing authorisation holders should also report follow-up information, where new administrative information is available, that could impact on the case management; for exa mple, if new case identifiers have become known to the sender, which may have been used in previous transmissions (data element ‘Other case identifiers in previous transmissions" (ICH-E2B(R2) A.1.11)). This information may be specifically relevant to manage potential duplicates". The marketing authorisation holder should therefore report the EMA world-wide unique case identifier as follow-up information for the individual case already existing in the marketing authorisation holder"s database to the receivers where the individual case was previously reported by the marketing authorisation holder. 00

5 For individual cases resulting from

the MLM service of the Agency and downloaded by the marketing authorisation holder from

EudraVigilance and imported to

the company"s safety database - can the marketing authorisation holder change the literature reports as per their own SOPs? The marketing authorisation holder can process the ICSRs originating from the new service in their safety database according to their own SOPs. The provisions set out in GVP Module VI and related guidance should be followed accordingly. More specifically, GVP Module VI, chapter VI.C.6.2.2.4."Case narrative, causality assessment and comments" states the following: "Where available, comments from the primary source on the diagnosis, causality assessment or other relevant issue, should be provided in the data element ‘Reporter"s comments" (ICH-E2B(R2) B.5.2). Competent authorities in Member States and marketing authorisation holders may provide an assessment of the case and describe a disagreement with, and/or alternatives to the diagnoses given by the primary source (see VI.C.6.2.2.3.). This should be done in the data element ‘Sender"s comments" (ICH-E2B(R2) B.5.4), where discrepancies or confusions in the information notified by the primary source may also be highlighted. Where applicable, a summary of the points of concerns and actions proposed should also be included in the data element ‘Sender"s comments" (ICH-E2B(R2)

B.5.4), if the ICSR leads to notification of an emerging safety issue (see VI.C.2.2.6.). The degree of

suspected relatedness of each medicinal product to the adverse reaction(s) may be indicated in the

data element ‘Relatedness of drug to reaction(s)/event(s)" (ICH-E2B(R2) B.4.k.18), which should be

Monitoring of medical literature and the entry of relevant information into the EudraVigilance database by the European Medicines Agency

EMA/848710/2016 Page 5/25

Reference

ID

Question Answer

repeated as necessary. This also allows presenting the degree of relatedness from different sources or with different methods of assessment

For guidance on

"downgrading" of individual cases refer to GVP Module VI, chapters VI.B.2. "Validation of reports" and VI.C.6.2.2.7. "Follow-up information". 00

6 Following the publication of the

detailed guide for the MLM service, I have a question regarding the inclusion and exclusion criteria for processing of

ICSRs. I note in the seriousness

quotesdbs_dbs47.pdfusesText_47

[PDF] Literrature

[PDF] lithiase urinaire pdf

[PDF] lithosphère asthénosphère

[PDF] lithosphère composition

[PDF] lithosphère continentale

[PDF] lithosphère continentale composition

[PDF] lithosphère définition

[PDF] lithosphère et asthénosphère première s

[PDF] lithosphère océanique définition

[PDF] Litlle Bear, Gamy pour le devoir sur les portails

[PDF] littéraire

[PDF] Littérature & philosophie - La relativité des savoir

[PDF] Littérature & Société

[PDF] Littérature - Dates Pléiade (début-fin)

[PDF] Littérature : Oedipe Roi help